Comparison of Saw Palmetto (extract and whole berry) and Cernitin on prostate growth in rats

Molecular and Cellular Biochemistry

Volumn 250, Issue 1-2, 2003, Pages 21-26

  Talpur, Nadeem ^a   Echard, Bobby ^a   Bagchi, Debasis ^b   Bagchi, Manashi ^b   Preuss, Harry G ^a  

^a GEORGETOWN UNIVERSITY MEDICAL CENTER   (United States)

^b CREIGHTON UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

Alpha blockers; Androgen induced prostatic hyperplasia; Benign prostatic hyperplasia (BPH); Castrated and non castrated rats; Cernitin; Finasteride; Saw Palmetto

Indexed keywords

CERNITIN; FINASTERIDE; NATURAL PRODUCT; SABAL EXTRACT; TERAZOSIN; TESTOSTERONE ENANTATE;

ANALYSIS OF VARIANCE; ANDROGEN METABOLISM; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CASTRATION; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFECT; DRUG POTENTIATION; DRUG RESEARCH; DRUG SAFETY; EVIDENCE BASED MEDICINE; HUMAN; IN VIVO STUDY; LONG TERM CARE; MALE; NONHUMAN; ORGAN WEIGHT; PROSTATE HYPERTROPHY; RAT; SYMPTOMATOLOGY; WEIGHT REDUCTION;

ANDROGENS; ANIMALS; BODY WEIGHT; CELL DIVISION; FRUIT; MALE; ORGAN SIZE; PLANT EXTRACTS; POLLEN; PROSTATE; RATS; SECALE CEREALE;

ANIMALIA; SABAL; SERENOA REPENS;

EID: 0041384103     PISSN: 03008177     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1024988929454     Document Type: Article

References (35)

1. Preuss HG, Adderly B: The Prostate Cure. Crown Publishers, Inc., New York, 1998, pp 1-251
2. Lytton B, Emery JM, Harvard BM: The incidence of benign prostatic obstruction. J Urol 99: 639-645, 1968
3. Kortt MA, Bootman JL: The economics of benign prostatic hyperplasia treatment: A literature review. Clin Ther 18: 1227-1241, 1996
4. Jacobsen SJ, Girman CJ, Guess HA, Oesterling JE, Lieber MM: New diagnostic and treatment guidelines for benign prostatic hyperplasia. Potential impact in the United States. Arch Intern Med 155: 477-481, 1995
5. Beisland HO, Binkowitz B, Brekkan E, Ekman P, Kontturi M, Lehtonen T, Lundmo P, Pappas F, Round E, Shapiro D: Scandinavian Clinical study of finasteride in the treatment of benign prostatic hyperplasia. Eur Urol 22: 271-277, 1992
6. The Finasteride (MK-906) study group in the treatment of benign prostatic hyperplasia. Prostate 22: 291-299, 1993
7. Gormley GJ, Stoner E, Bruskewitz RC, Imperato-McGinley J, Walsh PC, McConnell JD, Andriole GL, Geller J, Bracken BR, Tenover JS: The effect of finasteride in men with benign prostatic hyperplasia. The Finasteride Study Group. N Eng J Med 327: 1185-1191, 1992
8. Lepor H: Role of alpha-adrenergic blockers in the treatment of benign prostatic hyperplasia. Prostate 3(suppl): 75-84, 1990
9. Lepor H, Auerbach S, Puras-Baez A, Narayan P, Soloway M, Lowe F, Moon T, Leifer G, Madsen P: A randomized, placebo-controlled multicenter study of the efficacy and safety of terazosin in the treatment of benign prostatic hyperplasia. J Urol 148: 1467-1474, 1992
10. Stenger A, Tarayre JP, Carilla E: Etude pharmacologique et biochimique de l'extrait hexanique de serenoa repens. B: Gaz Med de France 89: 2041-2048, 1982
11. Ebeling L: The therapeutic results of defined pollen extract in patients with chronic prostatitis or BPH accompanied by chronic prostatitis. In: E. Schmiedt, J.E. Aiken, H.W. Bauer (eds). Therapy of Prostatitis. Zuckschwerdt Verlag, Munchen, 1986, pp 154-160
12. Leander G: A preliminary investigation on the therapeutic effect of Cernilton N in chronic prostatovesiculitis. Svenska Lakartidningen 59: 3296, 1962
13. Rhodes L, Primka RL, Berman C, Vergult G, Gabriel M, Pierre-Malice M, Gibelin B: Comparison of finasteride (Proscar), a 5α reductase inhibitor, and various commercial plant extracts in in vitro and in vivo 5α reductase inhibition. Prostate 22: 43-51, 1993
14. Dunnett C: A multiple comparison procedure for comparing several treatments with control. J Am Stat Assoc 50: 1096-1121, 1955
15. Wise GJ, Md, EO: Hormonal treatment of patients with benign prostatic hyperplasia: Pros and cons. Curr Urol Rep 2: 285-291, 2001
16. Wilt TJ, Howe W, MacDonald R: Terazosin for treating symptomatic benign prostatic obstruction: A systematic review of efficacy and adverse effects. BJU Int 89: 214-225, 2002
17. Champault G, Patel JC, Bonnard AM: A double-blind trial of an extract of the plant Serenoa repens in benign prostatic hyperplasia. Br J Clin Pharmacol 18: 461-462, 1984
18. Carraro JC, Raynaud JP, Koch G, Chisholm GD, Di Silverio F, Teillac P, Da Silva FC, Cauquil J, Chopin DK, Hamdy FC, Hanus M, Hauri D, Kalinteris A, Marencak J, Perier A, Perrin P: Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: a randomized international study of 1,098 patients. Prostate 29: 231-240, 1996
19. Plosker GL, Brogden RN: Serenoa repens (Permixon). A review of it pharmacology and therapeutic efficacy in benign prostatic hyperplasia. Drugs Aging 9: 379-395, 1996
20. Denis LJ: Editorial review of 'Comparison of phytotherapy (Permixon) with finasteride in the treatment of benign prostate hyperplasia: A randomized international study of 1,098 patients.' The Prostate 29: 241-242, 1996
21. Braeckman J: The extract of Serenoa repens in the treatment of benign prostatic hyperplasia: A multicenter open study. Curr Therap Res 56: 776-785, 1994
22. Yasumoto R, Kawanishi H, Tsujino T, Tsujita M, Nishisaka N, Horii A, Kishimoto T: Clinical evaluation of long-term treatment using cernitin pollen extract in patients with benign prostatic hyperplasia. Clin Ther 17: 82-87, 1995
23. Becker H, Ebeling L: Conservative treatment of benign prostatic hyperplasia (BPH) with Cernilton N. Results of a placebo-controlled double-blind study. Urologe B 28: 301-306, 1988
24. Becker H, Ebeling L: Phytotherapy of BPH with Cernilton N. Result of a controlled clinical study. Urologe B 31: 113-116, 1991
25. Buck AC, Rees RW, Ebeling L: Treatment of chronic prostatitis and prostatodynia with pollen extract. Br J Urol 64: 496-499, 1989
26. Buck AC, Cox R, Rees RW, Ebeling L, John A: Treatment of outflow tract obstruction due to benign prostatic hyperplasia with the pollen extract, Cernilton. A double-blind, placebo-controlled study. Br J Urol 66: 398-404, 1990
27. Maekawa M, Kishimoto T, Yasumoto R, Wada S, Harada T, Ohara T, Okajima E, Hirao Y, Ohzono S, Shimada K: Clinical evaluation of Cernilton on benign prostatic hypertrophy - a multiple center double-blind study with Paraprost. Hinyokika Kiyo 36: 495-516, 1990
28. Inada T, Kitagawa T, Miyakawa M: Use of Cernilton in Patients with Prostatic Hypertrophy. Tobishi Pharmaceutical Co. Ltd., Tokyo, Japan, 1966
29. Brauer H: The treatment of benign prostatic hyperplasia with phytopharmacia: A comparative study of Cernilton and beta sitosterol. Therapeiwoche 36: 1686-1696, 1986
30. Rugendorff EW, Weidner W, Ebeling L, Buck AC: Results of treatment with pollen extract (Cernilton N) in chronic prostatitis and prostatodynia. Br J Urol 71: 433-438, 1993
31. Sultan C, Terraza A, Devillier C, Carilla E, Briley M, Loire C, Descomps B: Inhibition of androgen metabolism and binding by a liposterolic extract of 'Serenoa repens B' in human foreskin fibroblasts. J Steroid Biochem 20: 515-519, 1984
32. Preuss HG, Marcusen C, Regan J, Klimberg IW, Welebir TA, Jones WA: Randomized trial of a combination of natural products (cernitin, saw palmetto, β-sitosterol, vitamin E) on symptoms of benign prostatic hyperplasia (BPH). Int Urol Nephrol 33: 217-225, 2001
33. Kamijo T, Sato S, Kitamura T: Effect of cernitin pollen-extract on experimental non-bacterial prostatitis in rats. Prostate 49: 122-131, 2001
34. Loschen G, Ebeling L: Inhibition of arachidonic acid cascade by extract of rye pollen. Arzneimittelforschung 41: 162-167, 1991
35. Breu W, Hagenlocher M, Redl K, Tittel G, Stadler F, Wagner H: Anti-inflammatory activity of sabal fruit extracts prepared with supercritical carbon dioxide. In vitro antagonists of cyclooxygenase and 5-lipoxygenase metabolism. Arzneimittelforschung 42: 547-551, 1992